Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

KEY publications
IPC's Chief Medical Officer has selected the following publications as important to the understanding of the impact of COVID-19 and psoriasis. 

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study. Satveer K. Mahil, Nick Dand, Kayleigh J. Mason, Zenas ZN. Yiu, Teresa Tsakok, Freya Meynell, Bola Coker, Helen McAteer, Lucy Moorhead, Teena Mackenzie, Maria Teresa Rossi, Raquel Rivera, Emmanuel Mahe, Andrea Carugno, Michela Magnano, Giulia Rech, Esther A. Balogh, Steven R. Feldman, Claudia De La Cruz, Siew Eng Choon, Luigi Naldi, Jo Lambert, Phyllis Spuls, Denis Jullien, Hervé Bachelez, Devon E. McMahon, Esther E. Freeman, Paolo Gisondi, Luis Puig, Richard B. Warren, Paola Di Meglio, Sinéad M. Langan, Francesca Capon, Christopher EM. Griffiths, Jonathan N. Barker, Catherine H. Smith. J Allergy Clin Immunol. 2020 Oct 16; S0091-6749(20)31413-5. doi: 10.1016/j.jaci.2020.10.007. [Epub ahead of print]

Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy. [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C.   2020;e13495. doi:10.1111/dth.13695.

 

Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemicLópez-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Clin Exp Dermatol. 2020 May 5. doi: 10.1111/ced.14275. [Epub ahead of print]

 

View all

this weeks' publications on covid-19 & psoriasis

Related Articles

Generalized pustular psoriasis following COVID-19.

Dermatol Ther. 2020 Nov 27;:e14595

Authors: Shahidi Dadras M, Diab R, Ahadi M, Abdollahimajd F

PMID: 33244885 [PubMed - as supplied by publisher]

VIEW ALL ON PUBMED

resources from our industry partners

 AbbVie
Amgen
Novartis
UCB

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK